CDK 4/6 inhibition
Interviews and expert commentary tagged “CDK 4/6 inhibition” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Audio Journal of Oncology
Paul H Cottu MD PhD, ESMO Berlin: Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer
Aan identifyable subset of patients with high-risk ER+ HER2- early breast cancer better off without chemotherapy
24 November 2025
0:00
Audio Journal of Oncology
John P. Crown MD MBA: ESMO 2025, Berlin: Adjuvant Ribociclib Brought Longer Freedom from Metastases for Patients with HR+/HER2- Early Breast Cancer: NATALEE Five Year Outcomes
John P. Crown MD MBA: ESMO 2025, Berlin: Adjuvant Ribociclib Brought Longer Freedom from Metastases for Patients with HR+/HER2- Early Breast Cancer: NATALEE Five Year Outcomes
24 October 2025
0:00